Pharma, US Government Plan for COVID-19 Booster Shots

It’s unclear how long protections against infection will last from the initial vaccinations, and health authorities say additional jabs will likely be necessary.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, CARMENGABRIELA

To stay protected against COVID-19, people may need booster shots within 12 months of receiving their initial vaccinations, David Kessler, the chief science officer for President Joe Biden’s COVID-19 response task force, said at a congressional committee meeting on Thursday (April 15), Reuters reports. Pfizer CEO Albert Bourla agrees with that timeline, according to comments he made to CNBC earlier this month.

So far, the evidence suggests that Pfizer/BioNTech’s and Moderna’s COVID-19 vaccines will protect against SARS-CoV-2 infection for at least six months. Beyond that, the data simply aren’t available yet.

“Unfortunately, many people have misunderstood that to mean that it lasts only six months, [when] all that information means is that we know that it lasts six months, and we expect it to last longer,” allergist and clinical immunologist Susan Bailey, the president of the American Medical Association, tells National Geographic.

Pfizer and BioNTech are ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies